SiREEN develops small molecule inhibitors to licensed and proprietary drug targets using their technology platforms SiREENize, SiREENscreen, and SiREENvalid.

History:

SiREEN was founded in January 2002. They merged with NADAG in early 2004 to become SIRENADE Pharmaceuticals.

Employment

Email:schaeffer@sireen.com

Fax:+49 89 700760-22

Mail:
SiREEN AG
Dr. Michael Sch‰ffer
IZB
Am Klopferspitz 19
82152 Martinsried
Tel.: +49 89 700760-17

General Info:

Ticker: private

Employees:

Regions:
Europe

Research Focus:
Disease

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: